2.

近期疗效亚组分析

Subgroup analysis of short term response

Agents	Total, n (%)	Response, n (%)				ORR, n (%)	DCR, n (%)
		CR	PR	SD	PD
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
Total	72 (100.0)	1 (1.4)	18 (25.0)	41 (56.9)	12 (16.7)	19 (26.4)	60 (83.3)
Pyrotinib+chemotherapy (±trastuzumab)
Pyrotinib+capecitabine	40 (55.6)	1 (2.5)	13 (32.5)	20 (50.0)	6 (15.0)	14 (35.0)	34 (85.0)
Pyrotinib+vinorelbine (oral)	12 (16.7)	0 (0)	0 (0)	9 (75.0)	3 (25.0)	0 (0)	9 (75.0)
Pyrotinib+etoposide (oral)	4 (5.6)	0 (0)	1 (25.0)	2 (50.0)	1 (25.0)	1 (25.0)	3 (75.0)
Pyrotinib+gemcitabine	2 (2.8)	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	2 (100.0)
Pyrotinib+paclitaxel	1 (1.4)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1 (100.0)
Pyrotinib+albumin-bound paclitaxel	1 (1.4)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1 (100.0)
Pyrotinib+trastuzumab+gemcitabine	1 (1.4)	0 (0)	1 (100.0)	0 (0)	0 (0)	1 (100.0)	1 (100.0)
Pyrotinib+trastuzumab+albumin-bound paclitaxel	1 (1.4)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)
Pyrotinib+endocrine therapy (±trastuzumab)
Pyrotinib+endocrine therapy	3 (4.2)	0 (0)	1 (33.3)	2 (66.7)	0 (0)	1 (33.3)	3 (100.0)
Pyrotinib+trastuzumab+endocrine therapy	3 (4.2)	0 (0)	2 (66.7)	1 (33.3)	0 (0)	2 (66.7)	3 (100.0)
Pyrotinib (±trastuzumab)
Pyrotinib alone	3 (4.2)	0 (0)	0 (0)	2 (66.7)	1 (33.3)	0 (0)	2 (66.7)
Pyrotinib+trastuzumab	1 (1.4)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1 (100.0)